Vertex Raises 2026 Revenue Guidance on Strong Second-Quarter Performance, Eyes Crinetics Acquisition
The biotech giant reported $3.33 billion in Q2 revenue and lifted full-year guidance as it prepares to add rare endocrine diseases as a fifth therapeutic pillar.
Strong Revenue Growth Drives Raised Guidance
Vertex Pharmaceuticals Incorporated reported second-quarter 2026 revenue of $3.33 billion, representing a 12% increase compared to the same period in 2025, according to an 8-K filing dated August 3, 2026. The Boston-based biotech raised its full-year revenue guidance to a range of $13.1 billion to $13.2 billion, up from prior guidance of $12.95 billion to $13.1 billion (8-K filing, 2026-08-03).
U.S. revenue increased 11% to $2.06 billion, driven by "continued strong CF patient demand, including from new initiations of ALYFTREK; higher realized net prices in CF versus the prior year; and contributions from CASGEVY and JOURNAVX," while international revenue rose 14% to $1.28 billion (8-K filing, 2026-08-03).
The company reported GAAP net income of $1.1 billion and non-GAAP net income of $1.2 billion for the quarter. Cash, cash equivalents, and marketable securities totaled $13.6 billion as of June 30, 2026, up from $12.3 billion at year-end 2025 (8-K filing, 2026-08-03).
Portfolio Diversification Gains Momentum
Vertex's diversification beyond cystic fibrosis continued to accelerate. CASGEVY, the company's gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, recorded revenue of $76 million, representing 78% sequential growth and 151% year-over-year growth (8-K filing, 2026-08-03).
The FDA recently approved CASGEVY for children as young as 2 years of age "in just 53 days post filing," expanding the eligible patient population by approximately 5,500 patients (8-K filing, 2026-08-03).
JOURNAVX, Vertex's non-opioid acute pain therapy, generated $50 million in revenue, reflecting 71% sequential growth. The company reported approximately 535,000 prescriptions filled in the second quarter alone, with roughly 260 million individuals in the U.S. now having reimbursed access (8-K filing, 2026-08-03).
Key Regulatory Milestones Ahead
Vertex disclosed that the FDA has set a PDUFA target action date of November 30, 2026, for povetacicept in IgA nephropathy (8-K filing, 2026-08-03). According to MarginX data, this date falls between two FOMC rate decisions scheduled for September 16 and October 28, 2026. If approved, povetacicept would become "the first commercialized therapy in Vertex's emerging nephrology pillar" (8-K filing, 2026-08-03).
The company continues to advance next-generation CF treatments, having completed dosing in a proof-of-concept study of VX-828 with results expected in the second half of 2026 (8-K filing, 2026-08-03).
Crinetics Acquisition to Add Fifth Pillar
Vertex entered into an agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026. CEO Reshma Kewalramani stated the pending acquisition will add "rare endocrine diseases as our fifth pillar, further diversifying our portfolio" (8-K filing, 2026-08-03).
The company noted that its 2026 financial guidance "does not reflect the impact of the pending acquisition" and will provide updated guidance following transaction close (8-K filing, 2026-08-03).
Operating expenses increased year-over-year, with combined GAAP R&D, acquired IPR&D, and SG&A expenses reaching $1.6 billion in the quarter, primarily due to "commercial investment to support the launch of JOURNAVX in acute pain and the build-out of the renal franchise, led by povetacicept in IgAN" (8-K filing, 2026-08-03). The company reiterated full-year expense guidance ranges.
MarginX data shows Vertex is expected to report third-quarter 2026 results on November 2, 2026, two days after the povetacicept PDUFA date.
This article was generated by MarginX from the 8-K filing on 2026-08-03. It is not investment advice.